Drug Pipeline

May 12, 2021

Longer half-lives mean less frequent administration and improved quality of life.

May 06, 2021

The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.

April 16, 2021

In this third part of a three-part series, Steven D. Pearson, M.D., M.Sc., founder and president of ICER talks the drug Inclisiran and its relation to PCSK9 inhibitors.

April 15, 2021

The triptans, long the workhorses of migraine treatment, have been joined by monoclonal antibodies and small-molecule drugs that block calcitonin gene-related peptide. What’s lacking is a precision approach to treatment based on biomarkers.

March 08, 2021

Will emerging variants make the leading vaccines less protective?

February 09, 2021

The COPD Foundation is calling for a change in clinical trial design that would test experimental therapies in subsets of patients.

February 01, 2021

Opinion piece by MHE's Editorial Advisory Board Member and CEO of The Pharmacy Group, Perry Cohen. Perry discusses the response differences and vague similarities between the countries and addresses the continuous question, "What is the new normal?"

January 15, 2021

The industry is adjusting to the pandemic, but FDA approvals could dip this year. Several new drugs for atopic dermatitis may get the agency’s green light.

December 16, 2020

Pre-pandemic momentum helped keep the number of novel therapies approved by the FDA high, and then COVID-19 tested just how fast the pipeline could adjust and expand.

November 27, 2020

Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.